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Abstract  
BACKGROUND: The sudden development of facial plaques and nodules may be an alarming clinical sign for 
underlying malignancies. Nevertheless, a broad range of inflammatory and infectious diseases must be 
considered as well in the differential diagnosis. 
CASE REPORT: We report on a 53-year-old male patient with a left-sided cheek infiltration with oozing but no 
lymphadenopathy. He had a medical history of head-and-neck cancer. The primary differential diagnosis was 
herpes zoster with secondary impetiginization or pyoderma facial. About eight weeks later, the patient presented 
with progressive formation of nodules and plaques on the face and isotretinoin was stopped. Skin biopsy 
suggested mycosis fungoid and an oral treatment with bexarotene was started. After limited response for another 
eight weeks, he returned later with massive facial swelling, nodules and impetiginization. Another skin biopsy was 
performed to exclude diagnostic error or investigate possible disease progression. Microscopic evaluation and 
multiplex-polymerase chain reaction confirmed the diagnosis of peripheral T-cell lymphoma, not otherwise 
specified (PTL-NOS), stage Ia (T1 N0 M0). Imaging techniques excluded metastatic spread. By interdisciplinary 
tumour board, R-CHOP (rituximab, cyclophosphamide, hydroxyl-doxorubicin, vincristine, and prednisolone) was 
recommended and initiated by hemato-oncologists. 
CONCLUSIONS: PLT-NOS confirmed in the present patient has a poor prognosis with a 5-year survival rate of 
less than 20%. 
Introduction 
 
Sudden development of indurated facial 
plaques refers to a broader range of benign but also 
serious life threatening diseases. Various 
inflammatory disorders are warranting consideration in 
the differential diagnosis. 
Pyoderma facial or rosacea fulminant is 
characterised by erythematous indurated and painful 
plaques, sometimes oozing. It can develop unilaterally 
but is a rare diagnosis in males in contrast to females 
[1]. Sweet syndrome is a rare neutrophilic disease 
with rapid onset, fever, neutrophilic leukocytosis and 
painful cutaneous plaques, which may involve the 
face [2]. 
Well’s syndrome or eosinophilic cellulitis is a 
rare disorder characterised by flame figures of 
eosinophils in dermal tissue. Pruritic cellulitis-like 
plaques may masquerade as bacterial facial infection 
[3]. Granuloma faciale is an uncommon, chronic 
inflammatory disorder initially described as 
eosinophilic granuloma, responding to corticosteroids, 
and shares the apple jelly phenomenon on diascopy 
with sarcoidosis [4]. 
Histiocytic diseases may affect the facial skin. 
Benign cutaneous Rosai-Dorfman disease - a rare, 
non-Langerhans cell histiocytosis, affects the facial 
skin in about 11% of cases with erythematous plaques 
[5]. Disseminated xanthogranuloma typically involves 
periorbital skin [6]. 
Among infectious disorders, cutaneous 
leishmaniasis is emerging in non-epidemic areas. The 
disease is caused by vector-borne protozoal 
cutaneous infection by several species of Leishmania 
transmitted by sandflies [7, 8].
 
 
Wollina et al. Peripheral T-Cell Lymphoma Not Otherwise Specified (NOS) 
______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2017 Jul 25; 5(4):476-479.                                                                                                                                                          477 
 
In the case of immunosuppression, bacterial 
papillomatosis and severe facial soft tissue infections 
may develop [9]. Invasive zygomycosis is another 
potentially fatal infection [10]. Malignancies need to be 
taken into consideration in any atypical case of facial 
nodular plaque-type affection, as the following case 
report illustrates. 
 
 
Case presentation 
 
A 53-year-old male patient was admitted to 
our hospital in July 2016 because of a left sided cheek 
infiltration with oozing. We observed an oozing 
indurated nodular plaque of about 6 x 8 cm (Fig. 1A) 
but no lymphadenopathy. The primary differential 
diagnosis was herpes zoster with secondary 
impetiginization or pyoderma facial.  
The patient was treated initially with oral 
acyclovir 5 x 800 mg /d plus 100 mg prednisolone/d 
(with tapering the dose) for seven days. Oozing 
diminished but infiltrates were still present.  
After that isotretinoin therapy was initiated. 
Topical treatment consisted of disinfectant washings 
and fusidinic acid ointment. The marked lymphedema 
could be explained by a history of head-and-neck 
cancer (T2 N2 M0 G2 V1 R0) the year before with 
surgery, neck dissection and radiotherapy.  
The patient returned in September 2016 (Fig. 
1B). Since there was progress with nodules and lid 
oedema, isotretinoin was stopped, and a skin biopsy 
was performed. The working diagnosis was mycosis 
fungoides. Based on the cutaneous T-cell lymphoma 
(CTCL) diagnosis the patient was discussed in the 
interdisciplinary tumour board. Radiotherapy was 
impossible due to the previous radiotherapy of head-
and-neck cancer. Therefore, oral treatment with 525 
mg/ d bexarotene was started. There was progress in 
December leading to a cessation of bexarotene (Fig. 
1C). 
 
Figure 1: Peripheral T-cell lymphoma, not otherwise specified. (A) 
Initial presentation resembling herpes infection; (B) Worsening with 
an aspect of mycosis fungoides; (C) Further progression with 
massive lid oedema and secondary impetiginization 
 
Another skin biopsy was performed. There 
was a dense inflammatory infiltrate in dermis and 
subcutis, but no interface dermatitis and no epidermal 
infiltration. Hair follicles were partly destroyed. The 
infiltrate consisted mostly of medium-sized 
polymorphous cells with notched nuclei and numerous 
mitoses. Some small lymphocytic cells and individual 
plasma cells and mast cells were intermingled (Fig. 2).  
 
Figure 2: Histologic investigations. (a) Dense dermal infiltrate 
(hematoxylin-eosin x 4); (b) Detail – mononuclear cells with cellular 
atypia and atypical mitoses (hematoxylin-eosin x 10); (c) Strong 
expression of CD3 (immunoperoxidase x 10); (d) CD8 expression 
(immunoperoxidase x 10); (e) Beta-F1 expression 
(immunoperoxidase x 4; (f) Ki67 for proliferating cells 
(immunoperoxidase x 4) 
 
Immunohistological findings are summarised 
in Table 1. After DNA extraction multiplex-polymerase 
chain reaction (PCR) had been performed to 
investigate clonality of cells (Institute of Pathology, 
University of Kiel, Germany) (Table 2). Monoclonality 
only could be demonstrated for T-cells, not B-cells. 
Table 1: Immunohistological findings 
Marker Reactivity 
CD1a + (for single cells only) 
CD3 +++ 
CD4 (+) 
CD5 + 
CD7 +++ 
CD8 +++ 
CD10 - 
CD20 + (focally in the surrounding tissue by small 
lymphocytes) 
CD30 - 
CD56 - 
CD68 + (for single histiocytes only) 
Bcl-6 - 
Beta-F1 (T-cell receptor beta 
chain) 
+++ 
Cyclin-D1 - 
Ki67 ++ (up to 60% of medium-sized cells) 
PD1 + 
Perforin - 
 
Imaging with diagnostic ultrasound and 
thoracic X-ray excluded metastatic spread. However, 
a parotic adenoma was identified. Laboratory 
investigations revealed an increased ratio of 
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CD3+CD4+/ CD3+CD8+ of 3.56 (normal range: 1.0-
2.3). 
The diagnosis of peripheral T-cell lymphoma, 
not otherwise specified (PTL-NOS), stage Ia (T1 N0 
M0), was confirmed. 
Table 2: Multiplex-PCR (bp – base pair; negative means 
polyclonality instead of monoclonality) 
Beta-chain T-cell receptor gene  monoclonality 
 A-multiplex PCR 247 & 248 bp 
 B-multiplex PCR 253 & 261 bp 
 C-multiplex PCR 193 & 303 bp 
Gamma-chain T-cell receptor gene   
 va-multiplex PCR negative 
 vb-multiplex PCR negative 
Immunoglobulin heavy chain gene   
 F1-multiplex PCR negative 
 F2-multiplex PCR negative 
 F3-multiplex PCR negative 
 
By interdisciplinary tumour board, R-CHOP 
(rituximab, cyclophosphamide, hydroxyl-doxorubicin, 
vincristine, and prednisolone) was recommended and 
initiated in January by hemato-oncologists. The 
treatment is continued.  
 
 
Discussion 
 
Peripheral T-cell lymphoma (PTL) NOS is a 
rare but aggressive malignancy. The initial stages 
often resemble non-malignant plaque-type or nodular 
dermatoses as in the present case. These primary 
lesions may become infected and imitate an infectious 
disease [11]. 
In the differential diagnosis, other lymphomas 
need to be considered. The most common CTCL – 
mycosis fungoides - was the first suspicion. The 
aggressive course and the missing epidermotropism 
of atypical cells argued against. Because of the 
dominance of CD8+ lymphocytes in the second 
biopsy, primary cutaneous CD8-positive aggressive 
epidermotropic T-cell lymphoma (CD8+ AECTCL) had 
to be considered. AECTL is characterised by rapidly 
evolving erosive or necrotic plaques and nodules. 
Epidermotropic infiltrates of CD8+ atypical 
lymphocytes are the hallmark of CD8+ AECTCL, 
which exhibits a poor prognosis [12]. Again, in the 
present case, there was no epidermotropism at all, 
confirming the diagnosis of PTL-NOS. 
PTL-NOS may present with single nodules or 
nodular plaques but tends to disseminate rapidly. 
Responses to radio- and chemotherapy a short-lived. 
Our patient has achieved a partial remission during R-
CHOP therapy [Rituximab, Cyclophosphamide, 
Hydroxydaunorubicin, Vincristine (Oncovin®), and 
Prednisolone].  
Negative prognostic factors for PTL-NOS are 
age > 60, Eastern Cooperative Oncology Group 
(ECOG) performance status of  2, lactate 
dehydrogenase levels at normal values or above, and 
involvement of the bone marrow are independent 
predictors of decreased survival [13]. Prognosis is 
poor even with stem cell transplantation and systemic 
chemotherapy and radiotherapy with a 5-year survival 
rate of less than 20% [14]. 
In conclusion, sudden development of facial 
plaques and nodules can be a red flag of unknown 
malignancy. Even if routine laboratory tests are 
unremarkable and lymphadenopathy is absent, an 
aggressive lymphoma-like PTL-NOS in this case, may 
be present. Repeated skin biopsies are needed to 
confirm or exclude diagnosis. PTL-NOS, however, has 
a poor prognosis not improved substantially by 
systemic treatment. 
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